Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary...

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Clinical Pharmacy

Background:

• Guideline discrepancies for CYP2C19 intermediate metabolizers may impede genotype-guided antiplatelet therapy post-percutaneous coronary intervention.
• Previous research highlights potential limitations in prescribing practices based on genetic profiles.

Purpose of the Study:

• To evaluate the impact of genotype-guided (PGx)-optimal antiplatelet therapy in CYP2C19 intermediate metabolizers.
• To identify factors associated with PGx-optimal therapy selection and clinical outcomes.

Main Methods:

• Single-center retrospective observational cohort study.
• Analysis of patients with CYP2C19 intermediate metabolizer status undergoing percutaneous coronary intervention.
• Comparison of outcomes between PGx-optimal and PGx-suboptimal therapy groups.

Main Results:

• Patients on PGx-optimal therapy were younger and less likely to be on anticoagulation (2% vs 12%, p=0.006).
• Commercial insurance was a significant predictor of PGx-optimal therapy selection (OR: 6.464, p<0.001).
• Anticoagulation use was associated with clopidogrel use (OR: 0.138, p=0.020).

Conclusions:

• No significant difference in major adverse cardiovascular events or bleeding was observed between PGx-optimal and suboptimal therapy groups.
• Anticoagulation use appears to influence clopidogrel prescribing, irrespective of PGx-optimal therapy.
• Factors like insurance status impact the selection of genotype-guided antiplatelet therapy.